OSUCCC's informatics program automates biosimilar selection, optimizing prior authorization and reducing administrative burdens, increasing biosimilar utilization by 21.9%. The program earned OSUCCC ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

In recent years, fed-batch biomanufacturing has begun giving way to continuous manufacturing processes, as developers face pressure to balance affordability with high manufacturing quality. Although ...

The Biologics Price Competition and Innovation Act of (BPCI Act) of 2009 granted responsibility to the FDA for review and approval of a new class of pharmaceuticals referred to as “Biosimilars.” (1) ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars is a biologic medication that is highly similar to an ...

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...

Biosimilars are a growing share of the U.S. pharmaceuticals market. But while there are at least 240 biosimilars in the development pipeline, just nine have achieved FDA approval and only three have ...

Please provide your email address to receive an email when new articles are posted on . Denosumab-bnht was approved as medication referencing Amgen’s Prolia and Xgeva. A settlement between Amgen and ...